Nektar Therapeutics (NKTR) Releases Earnings Results, Misses Expectations By $-0.03 EPS

Nektar Therapeutics (NKTR) reported quarterly earnings results on Wednesday, Aug-3-2016. The company reported $-0.36 earnings per share for the quarter, missing the analyst consensus estimate by $-0.03. Analysts had a consensus of $-0.33. The company posted revenue of $32.77 million in the period, compared to analysts expectations of $29.36 million. The company’s revenue was up 44.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-0.40 EPS.

Nektar Therapeutics closed down -0.58 points or -3.27% at $17.18 with 15,70,530 shares getting traded on Tusday. Post opening the session at $17.71, the shares hit an intraday low of $16.91 and an intraday high of $17.8 and the price fluctuated in this range throughout the day.Shares ended Tusday session in Red.

In a different news, on Jul 13, 2016, Jillian B. Thomsen (SVP & Chief Accounting Officer) sold 100,000 shares at $15.09 per share price. According to the SEC, on Jul 5, 2016, Robert Chess (director) sold 5,000 shares at $14.10 per share price. On May 18, 2016, John Nicholson (SVP & Chief Financial Officer) sold 856 shares at $13.58 per share price, according to the Form-4 filing with the securities and exchange commission.

Nektar Therapeutics is a clinical-stage biopharmaceutical company. The Company is engaged in the development of a pipeline of drug candidates that utilize its PEGylation and advanced polymer conjugate technology platforms which are designed to enable the development of new molecular entities that target known mechanisms of action. The Company’s pipeline is comprised of drug candidates for therapeutic areas including oncology pain anti-infectives and immunology. The Company’s research and development activities involve small molecule drugs peptides and other potential biologic drug candidates. Its drug candidates are designed to improve the pharmacokinetics pharmacodynamics half-life bioavailability metabolism or distribution of drugs and improve the overall benefits and use of a drug for the patient. Its polymer chemistry platform is being used to create specialized therapeutics including small molecule oral and parenteral drugs proteins peptides and antibody fragments.

Nektar Therapeutics

Leave a Reply

Nektar Therapeutics - Is it time to Sell?

Top Brokerage Firms are advising their investors on Nektar Therapeutics. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.